Atlas Trials

Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified

9 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified

RecordFirmDate
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas (NCT04074746)M.D. Anderson Cancer Center2020-07-18
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas (NCT03598998)City of Hope Medical Center2019-02-04
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin (NCT03278782)M.D. Anderson Cancer Center2017-11-14
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (NCT03075553)Mayo Clinic2017-05-17
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (NCT03017820)Mayo Clinic2017-04-04
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma (NCT03011814)City of Hope Medical Center2017-03-08
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma (NCT01590732)M.D. Anderson Cancer Center2012-10-29

Track Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified automatically

Every clearance here is in the API, with alerts when new ones post.